首页 > 最新文献

Cephalalgia最新文献

英文 中文
Headache in Sturge-Weber syndrome: A systematic review. 斯特格-韦伯综合征的头痛:系统综述。
IF 5 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-07-01 DOI: 10.1177/03331024241265881
Alessandro Ferretti, Marta Muscianese, Claudia Fanfoni, Giulia Bellone, Maurizio Mennini, Giovanni Di Nardo, Solmaz Abdolrahimzadeh, Gabriella De Marco, Alessandro Orsini, Thomas Foiadelli, Ilaria Frattale, Massimiliano Valeriani, Pasquale Parisi

Background: Sturge-Weber syndrome (SWS) is a neurocutaneous disorder for which the neurological aspects, particularly headaches, remain poorly understood, despite significantly affecting morbidity. The present study aimed to elucidate the prevalence, characteristics and treatment strategies, as well as explore the pathogenesis of headaches, in SWS.

Methods: Using Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, we systematically reviewed observational studies, case reports and series from eight databases (Cochrane Library, EBSCO, Embase, Medline, PubMed, Science Direct, Scopus and Web of Science), published from 1978 to 2023, to investigate the prevalence, characteristics, medication response and pathogenic theories of headaches in SWS.

Results: The review analyzed 48 studies, uncovering headache prevalence between 37% and 71%. Migraine-like headache affected up to 52% of individuals. Prophylactic and acute treatments included non-steroidal anti-inflammatory drugs, triptans and antiepileptic drugs, despite the lack of established guidelines. Life-threatening headaches in SWS are uncommon, typically accompanied by other neurological symptoms. The pathogenesis of headaches in SWS is considered to involve venous congestion and neuronal hyperexcitability linked to leptomeningeal angiomas.

Conclusions: Headaches occur more frequently in individuals with SWS than in the general population. Despite symptoms meeting migraine criteria, these headaches should be considered secondary to vascular conditions. Implementing acute and prophylactic treatment is advised to reduce the impact on patients' lives.

背景:斯特格-韦伯综合征(Sturge-Weber syndrome,SWS)是一种神经皮肤疾病,尽管对发病率有很大影响,但人们对其神经系统方面,尤其是头痛,仍然知之甚少。本研究旨在阐明 SWS 的发病率、特征和治疗策略,并探讨头痛的发病机制:采用系统综述和荟萃分析首选报告项目(PRISMA)指南,我们系统地回顾了从 1978 年到 2023 年期间发表的 8 个数据库(Cochrane Library、EBSCO、Embase、Medline、PubMed、Science Direct、Scopus 和 Web of Science)中的观察性研究、病例报告和系列研究,以调查 SWS 中头痛的患病率、特征、药物反应和致病理论:综述分析了 48 项研究,发现头痛发病率在 37% 至 71% 之间。偏头痛样头痛患者高达 52%。预防性治疗和急性治疗包括非甾体抗炎药、曲普坦和抗癫痫药,尽管缺乏既定的指导方针。威胁生命的 SWS 头痛并不常见,通常伴有其他神经系统症状。SWS头痛的发病机制被认为与静脉充血和神经元过度兴奋有关,而神经元过度兴奋又与脑膜下血管瘤有关:与普通人群相比,SWS 患者的头痛发生率更高。尽管症状符合偏头痛的标准,但这些头痛应被视为继发于血管疾病。建议实施急性和预防性治疗,以减少对患者生活的影响。
{"title":"Headache in Sturge-Weber syndrome: A systematic review.","authors":"Alessandro Ferretti, Marta Muscianese, Claudia Fanfoni, Giulia Bellone, Maurizio Mennini, Giovanni Di Nardo, Solmaz Abdolrahimzadeh, Gabriella De Marco, Alessandro Orsini, Thomas Foiadelli, Ilaria Frattale, Massimiliano Valeriani, Pasquale Parisi","doi":"10.1177/03331024241265881","DOIUrl":"10.1177/03331024241265881","url":null,"abstract":"<p><strong>Background: </strong>Sturge-Weber syndrome (SWS) is a neurocutaneous disorder for which the neurological aspects, particularly headaches, remain poorly understood, despite significantly affecting morbidity. The present study aimed to elucidate the prevalence, characteristics and treatment strategies, as well as explore the pathogenesis of headaches, in SWS.</p><p><strong>Methods: </strong>Using Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, we systematically reviewed observational studies, case reports and series from eight databases (Cochrane Library, EBSCO, Embase, Medline, PubMed, Science Direct, Scopus and Web of Science), published from 1978 to 2023, to investigate the prevalence, characteristics, medication response and pathogenic theories of headaches in SWS.</p><p><strong>Results: </strong>The review analyzed 48 studies, uncovering headache prevalence between 37% and 71%. Migraine-like headache affected up to 52% of individuals. Prophylactic and acute treatments included non-steroidal anti-inflammatory drugs, triptans and antiepileptic drugs, despite the lack of established guidelines. Life-threatening headaches in SWS are uncommon, typically accompanied by other neurological symptoms. The pathogenesis of headaches in SWS is considered to involve venous congestion and neuronal hyperexcitability linked to leptomeningeal angiomas.</p><p><strong>Conclusions: </strong>Headaches occur more frequently in individuals with SWS than in the general population. Despite symptoms meeting migraine criteria, these headaches should be considered secondary to vascular conditions. Implementing acute and prophylactic treatment is advised to reduce the impact on patients' lives.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhanced audiovisual associative pair learning in migraine without aura in adult patients: An unexpected finding. 成年无先兆偏头痛患者的视听联想对学习能力增强:意想不到的发现
IF 5 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-07-01 DOI: 10.1177/03331024241258722
Kálmán Tót, Gábor Braunitzer, Noémi Harcsa-Pintér, Ádám Kiss, Balázs Bodosi, János Tajti, Anett Csáti, Gabriella Eördegh, Attila Nagy

Background: Altered sensory processing in migraine has been demonstrated by several studies in unimodal, and especially visual, tasks. While there is some limited evidence hinting at potential alterations in multisensory processing among migraine sufferers, this aspect remains relatively unexplored. This study investigated the interictal cognitive performance of migraine patients without aura compared to matched controls, focusing on associative learning, recall, and transfer abilities through the Sound-Face Test, an audiovisual test based on the principles of the Rutgers Acquired Equivalence Test.

Materials and methods: The performance of 42 volunteering migraine patients was compared to the data of 42 matched controls, selected from a database of healthy volunteers who had taken the test earlier. The study aimed to compare the groups' performance in learning, recall, and the ability to transfer learned associations.

Results: Migraine patients demonstrated significantly superior associative learning as compared to controls, requiring fewer trials, and making fewer errors during the acquisition phase. However, no significant differences were observed in retrieval error ratios, generalization error ratios, or reaction times between migraine patients and controls in later stages of the test.

Conclusion: The results of our study support those of previous investigations, which concluded that multisensory processing exhibits a unique pattern in migraine. The specific finding that associative audiovisual pair learning is more effective in adult migraine patients than in matched controls is unexpected. If the phenomenon is not an artifact, it may be assumed to be a combined result of the hypersensitivity present in migraine and the sensory threshold-lowering effect of multisensory integration.

背景:多项关于单模态(尤其是视觉)任务的研究表明,偏头痛患者的感觉处理能力发生了改变。虽然有一些有限的证据暗示偏头痛患者的多感官处理能力可能会发生改变,但这方面的研究仍相对较少。本研究调查了无先兆偏头痛患者发作间期的认知表现,并与匹配的对照组进行了比较,重点是通过声-面测试(一种基于罗格斯后天等效性测试原理的视听测试)进行联想学习、回忆和迁移能力的测试:将 42 名自愿参加测试的偏头痛患者的表现与 42 名匹配对照组的数据进行比较,后者是从之前参加过该测试的健康志愿者数据库中挑选出来的。研究旨在比较两组患者在学习、回忆和迁移所学联想能力方面的表现:结果:与对照组相比,偏头痛患者的联想学习能力明显更强,所需的试验次数更少,在习得阶段出现的错误也更少。然而,在测试的后期阶段,偏头痛患者与对照组在检索错误率、泛化错误率或反应时间方面没有明显差异:我们的研究结果支持之前的研究,这些研究认为偏头痛患者的多感官处理表现出一种独特的模式。与匹配的对照组相比,成年偏头痛患者的视听配对联想学习更为有效,这一具体发现出乎意料。如果这一现象不是伪造的,那么可以认为它是偏头痛患者的超敏反应和多感官整合的感觉阈值降低效应共同作用的结果。
{"title":"Enhanced audiovisual associative pair learning in migraine without aura in adult patients: An unexpected finding.","authors":"Kálmán Tót, Gábor Braunitzer, Noémi Harcsa-Pintér, Ádám Kiss, Balázs Bodosi, János Tajti, Anett Csáti, Gabriella Eördegh, Attila Nagy","doi":"10.1177/03331024241258722","DOIUrl":"https://doi.org/10.1177/03331024241258722","url":null,"abstract":"<p><strong>Background: </strong>Altered sensory processing in migraine has been demonstrated by several studies in unimodal, and especially visual, tasks. While there is some limited evidence hinting at potential alterations in multisensory processing among migraine sufferers, this aspect remains relatively unexplored. This study investigated the interictal cognitive performance of migraine patients without aura compared to matched controls, focusing on associative learning, recall, and transfer abilities through the Sound-Face Test, an audiovisual test based on the principles of the Rutgers Acquired Equivalence Test.</p><p><strong>Materials and methods: </strong>The performance of 42 volunteering migraine patients was compared to the data of 42 matched controls, selected from a database of healthy volunteers who had taken the test earlier. The study aimed to compare the groups' performance in learning, recall, and the ability to transfer learned associations.</p><p><strong>Results: </strong>Migraine patients demonstrated significantly superior associative learning as compared to controls, requiring fewer trials, and making fewer errors during the acquisition phase. However, no significant differences were observed in retrieval error ratios, generalization error ratios, or reaction times between migraine patients and controls in later stages of the test.</p><p><strong>Conclusion: </strong>The results of our study support those of previous investigations, which concluded that multisensory processing exhibits a unique pattern in migraine. The specific finding that associative audiovisual pair learning is more effective in adult migraine patients than in matched controls is unexpected. If the phenomenon is not an artifact, it may be assumed to be a combined result of the hypersensitivity present in migraine and the sensory threshold-lowering effect of multisensory integration.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141878455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to: Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. 更正:基于患者性别的降钙素基因相关肽(CGRP)靶向疗法对急性和预防性偏头痛治疗效果的评估。
IF 5 2区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.1177/03331024241254952
{"title":"Corrigendum to: Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.","authors":"","doi":"10.1177/03331024241254952","DOIUrl":"https://doi.org/10.1177/03331024241254952","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypersensitivity to CGRP as a predictive biomarker of migraine prevention with erenumab. 对 CGRP 的超敏反应是使用艾伦单抗预防偏头痛的预测性生物标志物。
IF 5 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-06-01 DOI: 10.1177/03331024241258734
Haidar M Al-Khazali, Håkan Ashina, Rune Häckert Christensen, Astrid Wiggers, Kathrine Rose, Afrim Iljazi, Faisal Mohammad Amin, Messoud Ashina, Josefin Snellman, Tina Maio-Twofoot, Henrik W Schytz

Background: The present study aimed to investigate the predictive value of calcitonin gene-related peptide (CGRP)-induced migraine attacks for effectiveness to erenumab treatment in people with migraine.

Methods: In total, 139 participants with migraine underwent a single experimental day involving a 20-min infusion with CGRP. Following this, the participants entered a 24-week treatment period with erenumab. The primary endpoints were the predictive value of CGRP-induced migraine attacks on the effectiveness of erenumab, defined as ≥50% reduction in monthly migraine days, or ≥ 50% reduction in either monthly migraine or monthly headache days of moderate to severe intensity.

Results: Among participants with CGRP-induced migraine attacks, 60 of 99 (61%) achieved ≥50% reduction in monthly migraine days during weeks 13-24 with erenumab. Conversely, 13 of 25 (52%) where CGRP infusion did not induce a migraine achieved the same endpoint (p = 0.498). There were no significant differences between the ≥50% reduction in either monthly migraine or monthly headache days of moderate to severe intensity between CGRP-sensitive and non-sensitive participants (p = 0.625).

Conclusions: Our findings suggest that the CGRP-provocation model cannot be used to predict erenumab's effectiveness. It remains uncertain whether this finding extends to other monoclonal antibodies targeting the CGRP ligand or to gepants.Trial Registration: The study was registered at ClinicalTrials.gov (NCT04592952).

研究背景本研究旨在探讨降钙素基因相关肽(CGRP)诱导的偏头痛发作对偏头痛患者接受艾伦单抗治疗效果的预测价值:共有139名偏头痛患者接受了单日实验,其中包括20分钟的CGRP输注。之后,参与者进入为期24周的艾伦单抗治疗期。主要终点是CGRP诱导的偏头痛发作对艾伦单抗疗效的预测价值,即每月偏头痛天数减少≥50%,或每月偏头痛或每月中重度头痛天数减少≥50%:在CGRP诱发偏头痛发作的参与者中,99人中有60人(61%)在使用艾伦单抗的第13-24周期间每月偏头痛发作天数减少了≥50%。相反,在输注 CGRP 没有诱发偏头痛的 25 人中,有 13 人(52%)达到了同样的终点(p = 0.498)。对CGRP敏感和不敏感的参与者每月偏头痛或每月中重度头痛天数减少≥50%之间没有明显差异(p = 0.625):我们的研究结果表明,CGRP诱发模型不能用于预测艾伦单抗的疗效。目前仍不确定这一发现是否适用于其他靶向CGRP配体的单克隆抗体或抗凝血剂:该研究已在ClinicalTrials.gov(NCT04592952)上注册。
{"title":"Hypersensitivity to CGRP as a predictive biomarker of migraine prevention with erenumab.","authors":"Haidar M Al-Khazali, Håkan Ashina, Rune Häckert Christensen, Astrid Wiggers, Kathrine Rose, Afrim Iljazi, Faisal Mohammad Amin, Messoud Ashina, Josefin Snellman, Tina Maio-Twofoot, Henrik W Schytz","doi":"10.1177/03331024241258734","DOIUrl":"10.1177/03331024241258734","url":null,"abstract":"<p><strong>Background: </strong>The present study aimed to investigate the predictive value of calcitonin gene-related peptide (CGRP)-induced migraine attacks for effectiveness to erenumab treatment in people with migraine.</p><p><strong>Methods: </strong>In total, 139 participants with migraine underwent a single experimental day involving a 20-min infusion with CGRP. Following this, the participants entered a 24-week treatment period with erenumab. The primary endpoints were the predictive value of CGRP-induced migraine attacks on the effectiveness of erenumab, defined as ≥50% reduction in monthly migraine days, or ≥ 50% reduction in either monthly migraine or monthly headache days of moderate to severe intensity.</p><p><strong>Results: </strong>Among participants with CGRP-induced migraine attacks, 60 of 99 (61%) achieved ≥50% reduction in monthly migraine days during weeks 13-24 with erenumab. Conversely, 13 of 25 (52%) where CGRP infusion did not induce a migraine achieved the same endpoint (<i>p</i> = 0.498). There were no significant differences between the ≥50% reduction in either monthly migraine or monthly headache days of moderate to severe intensity between CGRP-sensitive and non-sensitive participants (<i>p</i> = 0.625).</p><p><strong>Conclusions: </strong>Our findings suggest that the CGRP-provocation model cannot be used to predict erenumab's effectiveness. It remains uncertain whether this finding extends to other monoclonal antibodies targeting the CGRP ligand or to gepants.<b>Trial Registration:</b> The study was registered at ClinicalTrials.gov (NCT04592952).</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
REPLY to Comment on Correlation between endometriosis and migraine features: Results from a prospective case-control study'': Correlation between endometriosis and migraine features is not based on a broad strokes results. REPLY to Comment on Correlation between endometriosis and migraine features:一项前瞻性病例对照研究的结果'':子宫内膜异位症与偏头痛特征之间的相关性并非基于一刀切的结果。
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.1177/03331024241254821
Caterina Exacoustos, Francesco Giuseppe Martire, Maria Albanese, Aikaterini Selntigia
{"title":"REPLY to Comment on Correlation between endometriosis and migraine features: Results from a prospective case-control study'': Correlation between endometriosis and migraine features is not based on a broad strokes results.","authors":"Caterina Exacoustos, Francesco Giuseppe Martire, Maria Albanese, Aikaterini Selntigia","doi":"10.1177/03331024241254821","DOIUrl":"https://doi.org/10.1177/03331024241254821","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141305550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Registry-based safety studies of migraine drugs in pregnancy: Acknowledging our failures. 以登记为基础的妊娠期偏头痛药物安全性研究:承认我们的失败
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.1177/03331024241262486
Alain Braillon
{"title":"Registry-based safety studies of migraine drugs in pregnancy: Acknowledging our failures.","authors":"Alain Braillon","doi":"10.1177/03331024241262486","DOIUrl":"https://doi.org/10.1177/03331024241262486","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Visual snow syndrome or "what's in a name?" 视觉雪综合症或 "名字里有什么"?
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.1177/03331024241259359
Gordon T Plant
{"title":"Visual snow syndrome or \"what's in a name?\"","authors":"Gordon T Plant","doi":"10.1177/03331024241259359","DOIUrl":"10.1177/03331024241259359","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141287853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Onabotulinumtoxina (craniotomy scar combined with cranial suture line injections) for persistent post craniotomy headache: Case series with long-term follow-up. Onabotulinumtoxina (开颅手术疤痕联合头颅缝合线注射)治疗开颅手术后顽固性头痛:长期随访的病例系列。
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.1177/03331024241259452
Janet Leon, Todd D Rozen, Alok A Bhatt

Background: There is no defined preventive treatment protocol for persistent post-craniotomy headache. In several small case series and individual case reports onabotulinumtoxinA injected into the craniotomy scar has shown possible efficacy. What is lacking is long term follow-up and if focusing on the cranial suture lines along with the craniotomy scar can enhance improvement and provide more sustained benefit.

Methods: Retrospective chart review with case series.

Results: Four patients (three women, one man) with ICHD-3 defined persistent post craniotomy headache were treated using a novel onabotulinumtoxinA injection protocol. All the patients presented with continuous head pain of moderate to severe intensity. All had severe allodynia on the side of their craniotomy. All had significant reduction in quality of life. Our application of onabotulinumtoxinA involved injection into both the surgical scar and the transected/irritated cranial suture lines noted on neuroimaging and physical examination. With treatment all patients demonstrated significant benefit including a reduction in daily pain intensity (75%-100%), developing periods of pain freedom (2-7 days per week) and having a dramatic improvement in quality of life (close to 100% in all). The benefit was sustained for at least five years of follow-up.

Conclusion: From our case series it appears that injection not only along the painful craniotomy scar but into the involved cranial suture lines provides positive efficacy and sustained improvement in patients with persistent post craniotomy headache.

背景:对于开颅手术后的持续性头痛,目前尚无明确的预防性治疗方案。在几个小型病例系列和个别病例报告中,在开颅手术瘢痕处注射阿博毒素显示了可能的疗效。目前缺乏的是长期随访,以及关注颅骨缝合线和开颅手术疤痕是否能加强改善并提供更持久的疗效:方法:回顾性病历审查和病例系列:结果:四名患有 ICHD-3 定义的开颅术后顽固性头痛的患者(三名女性,一名男性)接受了新颖的阿糖胞苷注射方案的治疗。所有患者均表现为中度至重度的持续性头部疼痛。所有患者的开颅手术侧都有严重的异感。所有患者的生活质量都明显下降。我们在手术疤痕和神经影像学检查和体格检查中发现的横断/刺激性颅骨缝合线上注射了奥博毒素。通过治疗,所有患者都获得了明显的疗效,包括日常疼痛强度降低(75%-100%)、疼痛缓解期延长(每周 2-7 天)以及生活质量大幅提高(所有患者的生活质量均接近 100%)。这种益处至少持续了五年:从我们的病例系列中可以看出,不仅沿着开颅手术后疼痛的疤痕注射,而且在受累的颅骨缝合线注射,对开颅手术后的顽固性头痛患者具有积极的疗效和持续的改善作用。
{"title":"Onabotulinumtoxina (craniotomy scar combined with cranial suture line injections) for persistent post craniotomy headache: Case series with long-term follow-up.","authors":"Janet Leon, Todd D Rozen, Alok A Bhatt","doi":"10.1177/03331024241259452","DOIUrl":"https://doi.org/10.1177/03331024241259452","url":null,"abstract":"<p><strong>Background: </strong>There is no defined preventive treatment protocol for persistent post-craniotomy headache. In several small case series and individual case reports onabotulinumtoxinA injected into the craniotomy scar has shown possible efficacy. What is lacking is long term follow-up and if focusing on the cranial suture lines along with the craniotomy scar can enhance improvement and provide more sustained benefit.</p><p><strong>Methods: </strong>Retrospective chart review with case series.</p><p><strong>Results: </strong>Four patients (three women, one man) with ICHD-3 defined persistent post craniotomy headache were treated using a novel onabotulinumtoxinA injection protocol. All the patients presented with continuous head pain of moderate to severe intensity. All had severe allodynia on the side of their craniotomy. All had significant reduction in quality of life. Our application of onabotulinumtoxinA involved injection into both the surgical scar and the transected/irritated cranial suture lines noted on neuroimaging and physical examination. With treatment all patients demonstrated significant benefit including a reduction in daily pain intensity (75%-100%), developing periods of pain freedom (2-7 days per week) and having a dramatic improvement in quality of life (close to 100% in all). The benefit was sustained for at least five years of follow-up.</p><p><strong>Conclusion: </strong>From our case series it appears that injection not only along the painful craniotomy scar but into the involved cranial suture lines provides positive efficacy and sustained improvement in patients with persistent post craniotomy headache.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141316856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to "Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials". 评估 CGRP mAbs 和 gepants 预防治疗偏头痛的疗效:第 3 期随机对照试验的系统综述和网络荟萃分析 "的更正。
IF 5 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-06-01 DOI: 10.1177/03331024241255216
{"title":"Corrigendum to \"Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials\".","authors":"","doi":"10.1177/03331024241255216","DOIUrl":"https://doi.org/10.1177/03331024241255216","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141455671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Latent class analysis of migraine associated vestibular-auditory symptoms. 偏头痛相关前庭-听觉症状的潜类分析。
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.1177/03331024241262488
Hui Li, Xiaonuo Xu, Rongjiang Xu, Ping Xiao Fan, Jiying Zhou, Liang Dong

Objective: This study aimed to identify the potential subgroups of migraines based on the patterns of migraine associated symptoms, vestibular and auditory symptoms using latent class analysis and to explore their characteristics.

Method: A total of 555 patients with migraine participated in the study. Symptoms such as nausea, vomiting, photophobia, phonophobia, osmophobia, visual symptoms, vestibular symptoms (dizziness, vertigo), and auditory symptoms (tinnitus, hearing loss, aural fullness) were assessed. Latent class analysis was performed to identify subgroups of migraines. Covariates such as gender, age of migraine onset, frequency of migraine attacks per month, and family history were also considered.

Results: The analysis revealed four latent classes: the Prominent Vestibular; Prominent Nausea; Presenting Symptoms but not prominent or dominant; and Sensory Hypersensitivity groups. Various covariates, such as gender, age of migraine onset, and frequency of migraine attacks, demonstrated significant differences among the four groups. The Sensory Hypersensitivity group showed the presence of multiple sensory symptoms, earlier age of migraine onset, and higher proportion of females. The Prominent Vestibular group had the highest probability of dizziness or vertigo but lacked the presence of auditory symptoms. The Prominent Nausea group exhibited prominent nausea. The Presenting Symptoms but not prominent or dominant group comprised individuals with the highest migraine attacks per month and proportion of chronic migraine.

Conclusion: This study identifies four subgroups of migraines based on the patterns of symptoms. The findings suggest potential different but overlapped mechanisms behind the vestibular and auditory symptoms of migraine. Considering the different patterns of migraine-related symptoms may provide deeper insights for patients' prognosis and clinical decision-making.

目的:本研究旨在根据偏头痛相关症状、前庭症状和听觉症状的模式,采用潜类分析法确定偏头痛的潜在亚组,并探讨其特征:本研究旨在利用潜类分析法,根据偏头痛相关症状、前庭症状和听觉症状的模式确定偏头痛的潜在亚组,并探讨其特征:方法:共有 555 名偏头痛患者参与研究。评估的症状包括恶心、呕吐、畏光、畏声、畏湿、视觉症状、前庭症状(头晕、眩晕)和听觉症状(耳鸣、听力下降、听觉饱胀)。对偏头痛进行了潜类分析,以确定偏头痛的亚组。此外,还考虑了性别、偏头痛发病年龄、偏头痛每月发作频率和家族史等协变量:分析结果显示了四个潜在类别:前庭症状突出组、恶心症状突出组、出现症状但不突出或不明显组和感觉过敏组。性别、偏头痛发病年龄和偏头痛发作频率等各种协变量在四个组别之间存在显著差异。感觉过敏组表现出多种感觉症状,偏头痛发病年龄较早,女性比例较高。前庭突出组出现头晕或眩晕的概率最高,但没有听觉症状。恶心症状突出组有突出的恶心症状。出现症状但不突出或不占优势组包括每月偏头痛发作次数和慢性偏头痛比例最高的人群:本研究根据症状模式确定了偏头痛的四个亚组。研究结果表明,偏头痛的前庭和听觉症状背后可能存在不同但重叠的机制。考虑偏头痛相关症状的不同模式可为患者的预后和临床决策提供更深入的见解。
{"title":"Latent class analysis of migraine associated vestibular-auditory symptoms.","authors":"Hui Li, Xiaonuo Xu, Rongjiang Xu, Ping Xiao Fan, Jiying Zhou, Liang Dong","doi":"10.1177/03331024241262488","DOIUrl":"https://doi.org/10.1177/03331024241262488","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to identify the potential subgroups of migraines based on the patterns of migraine associated symptoms, vestibular and auditory symptoms using latent class analysis and to explore their characteristics.</p><p><strong>Method: </strong>A total of 555 patients with migraine participated in the study. Symptoms such as nausea, vomiting, photophobia, phonophobia, osmophobia, visual symptoms, vestibular symptoms (dizziness, vertigo), and auditory symptoms (tinnitus, hearing loss, aural fullness) were assessed. Latent class analysis was performed to identify subgroups of migraines. Covariates such as gender, age of migraine onset, frequency of migraine attacks per month, and family history were also considered.</p><p><strong>Results: </strong>The analysis revealed four latent classes: the Prominent Vestibular; Prominent Nausea; Presenting Symptoms but not prominent or dominant; and Sensory Hypersensitivity groups. Various covariates, such as gender, age of migraine onset, and frequency of migraine attacks, demonstrated significant differences among the four groups. The Sensory Hypersensitivity group showed the presence of multiple sensory symptoms, earlier age of migraine onset, and higher proportion of females. The Prominent Vestibular group had the highest probability of dizziness or vertigo but lacked the presence of auditory symptoms. The Prominent Nausea group exhibited prominent nausea. The Presenting Symptoms but not prominent or dominant group comprised individuals with the highest migraine attacks per month and proportion of chronic migraine.</p><p><strong>Conclusion: </strong>This study identifies four subgroups of migraines based on the patterns of symptoms. The findings suggest potential different but overlapped mechanisms behind the vestibular and auditory symptoms of migraine. Considering the different patterns of migraine-related symptoms may provide deeper insights for patients' prognosis and clinical decision-making.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cephalalgia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1